Cancer Associated Fibroblasts express pro-inflammatory factors in human breast and ovarian tumors

Biochemical and Biophysical Research Communications

Volumn 437, Issue 3, 2013, Pages 397-402

  Erez, Neta ^a   Glanz, Sarah ^a   Raz, Yael ^a   Avivi, Camilla ^a   Barshack, Iris ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Breast cancer; CAFs; Inflammation; Ovarian cancer; Tumor microenvironment

Indexed keywords

CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; I KAPPA B; INTERLEUKIN 6;

ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER ASSOCIATED FIBROBLAST; CELL TYPE; CLINICAL ARTICLE; FEMALE; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INFLAMMATION; INTRADUCTAL CARCINOMA; LEUKOCYTE; OVARY TUMOR; PRIORITY JOURNAL; SKIN CARCINOMA; STROMA; UPREGULATION;

BREAST CANCER; CAFS; INFLAMMATION; OVARIAN CANCER; TUMOR MICROENVIRONMENT;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOKINE CXCL1; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; NF-KAPPA B; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880934991     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.06.089     Document Type: Article

References (40)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
3. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., Schnitt S., Sellers W.R., Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
4. Bhowmick N.A., Neilson E.G., Moses H.L. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337.
5. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
6. Erez N., Truitt M., Olson P., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147.
7. Mantovani A. La mala educacion of tumor-associated macrophages: diverse pathways and new players. Cancer Cell 2010, 17:111-112.
8. Servais C., Erez N. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J. Pathol. 2013, 229:198-207.
9. Quante M., Tu S.P., Tomita H., Gonda T., Wang S.S., Takashi S., Baik G.H., Shibata W., Diprete B., Betz K.S., Friedman R., Varro A., Tycko B., Wang T.C. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19:257-272.
10. Mantovani A., Marchesi F., Porta C., Sica A., Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast 2007, 16(Suppl. 2):S27-S33.
11. Shan W., Liu J. Inflammation: a hidden path to breaking the spell of ovarian cancer. Cell Cycle 2009, 8:3107-3111.
12. Condeelis J., Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266.
13. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., Coussens L.M. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
14. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J.Q., Hoffman R.M., Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANKsignalling. Nature 2011, 470:548-553.
15. DeNardo D.G., Coussens L.M. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9:212.
16. Lewis C.E., Hughes R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res. 2007, 9:209.
17. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
18. Calogero R.A., Cordero F., Forni G., Cavallo F. Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice. Breast Cancer Res. 2007, 9:211.
19. Biswas D.K., Shi Q., Baily S., Strickland I., Ghosh S., Pardee A.B., Iglehart J.D. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. USA 2004, 101:10137-10142.
20. Liu M., Sakamaki T., Casimiro M.C., Willmarth N.E., Quong A.A., Ju X., Ojeifo J., Jiao X., Yeow W.S., Katiyar S., Shirley L.A., Joyce D., Lisanti M.P., Albanese C., Pestell R.G. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 2010, 70:10464-10473.
21. Shostak K., Chariot A. NF-kappaB, stem cells and breast cancer: the links get stronger. Breast Cancer Res. 2011, 13:214.
22. Walker R.A. The complexities of breast cancer desmoplasia. Breast Cancer Res. 2001, 3:143-145.
23. Radisky E.S., Radisky D.C. Stromal induction of breast cancer: inflammation and invasion. Rev. Endocr. Metab. Disord. 2007, 8:279-287.
24. Labiche A., Heutte N., Herlin P., Chasle J., Gauduchon P., Elie N. Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma. Int. J. Gynecol. Cancer 2010, 20:28-33.
25. Schauer I.G., Sood A.K., Mok S., Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 2011, 13:393-405.
26. Halpern J.L., Kilbarger A., Lynch C.C. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor. Cancer Lett. 2011, 308:91-99.
27. Kim M.Y., Oskarsson T., Acharyya S., Nguyen D.X., Zhang X.H., Norton L., Massague J. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
28. Howe L.R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007, 9:210.
29. Marotta L.L., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., Bloushtain-Qimron N., Kim J.J., Choudhury S.A., Maruyama R., Wu Z., Gonen M., Mulvey L.A., Bessarabova M.O., Huh S.J., Silver S.J., Kim S.Y., Park S.Y., Lee H.E., Anderson K.S., Richardson A.L., Nikolskaya T., Nikolsky Y., Liu X.S., Root D.E., Hahn W.C., Frank D.A., Polyak K. TheJAK2/STAT3 signaling pathway is required for growth of CD44+ CD24- stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121:2723-2735.
30. Tawara K., Oxford J.T., Jorcyk C.L. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag. Res. 2011, 3:177-189.
31. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
32. Kerlikowske K., Molinaro A.M., Gauthier M.L., Berman H.K., Waldman F., Bennington J., Sanchez H., Jimenez C., Stewart K., Chew K., Ljung B.M., Tlsty T.D. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J. Natl. Cancer Inst. 2010, 102:627-637.
33. Takaishi K., Komohara Y., Tashiro H., Ohtake H., Nakagawa T., Katabuchi H., Takeya M. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010, 101:2128-2136.
34. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res. 2005, 65:10794-10800.
35. Agarwal A., Tressel S.L., Kaimal R., Balla M., Lam F.H., Covic L., Kuliopulos A. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res. 2010, 70:5880-5890.
36. Harris R.E., Beebe-Donk J., Doss H., Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol. Rep. 2005, 13:559-583.
37. Yang G., Rosen D.G., Liu G., Yang F., Guo X., Xiao X., Xue F., Mercado-Uribe I., Huang J., Lin S.H., Mills G.B., Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin. Cancer Res. 2010, 16:3875-3886.
38. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
39. Jones R.L., Rojo F., A'Hern R., Villena N., Salter J., Corominas J.M., Servitja S., Smith I.E., Rovira A., Reis-Filho J.S., Dowsett M., Albanell J. Nuclear NF-kappaB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J. Clin. Pathol. 2011, 64:130-135.
40. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat. Immunol. 2011, 12:715-723.